MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

Richard Wilson, Mark Middleton, Jennifer Houlden, Sandra Van Schaeybroeck, Christian Rolfo, Elena Elez, Julien Taieb, Thierry Andre, alberto Bardelli, Pierre Laurent=puig, Josef Tabernero, Marc Peeters, Tim Maughan, C Roberts, Sharon Love, Mark Lawler, Manuel Salto-Tellez, Margaret Grayson, Vlad Popovici, Federica Di Nicolantonio

Research output: Contribution to journalMeeting abstractpeer-review

Fingerprint Dive into the research topics of 'MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences